Cases Aleix, Portolés José, Calls Jordi, Martinez-Castelao Alberto, Munar María Antonia, Segarra Alfonso
Servicio de Nefrología, Hospital Clínic, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain,
Int Urol Nephrol. 2014 Oct;46(10):1983-95. doi: 10.1007/s11255-014-0800-4. Epub 2014 Aug 14.
To assess whether the correction dose recommended by the summary of product characteristics was adequate and to confirm the adequacy of the recommended conversion dosing strategies from shorter-acting erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator (C.E.R.A) in anaemic chronic kidney disease (CKD) patients in the clinical setting.
This was a 12-month, multicenter, prospective, observational study in anaemic CKD patients on haemodialysis and not on dialysis receiving C.E.R.A (at least one dose).
A total of 227 patients were included (not on dialysis; n = 142; haemodialysis: n = 85). The present analysis was conducted on ESA-naïve patients (not on dialysis: n = 31) and patients switched from other ESA (not on dialysis: n = 63; haemodialysis: n = 57). Both on and not on dialysis patients switched from other ESA received lower starting C.E.R.A doses than those recommended, and remained stable during the 12-month period. The higher the previous ESA dose was, the more beneficial the C.E.R.A dose conversion factor was. The proportion of patients with stable haemoglobin within the target range (11-13 g/dL) did not vary during the 12-month period both in nondialysis CKD patients and in those undergoing dialysis [baseline: 42 (66.7 %) and 34 (59.6 %); month 6: 21 (55.3 %) and 26 (50.0 %); month 12: 20 (64.5 %) and 25 (69.4 %), respectively]. In naïve patients, the mean weight-adjusted C.E.R.A dose during the study (1.19 ± 0.49 µg/kg/month) was similar to the recommended one. C.E.R.A was well tolerated.
Conversion from shorter-acting ESAs to C.E.R.A doses lower than those recommended can efficiently maintain target haemoglobin levels both in nondialysis and haemodialysis CKD patients, particularly when switching from higher ESA doses. A monthly C.E.R.A dose of 1.2 µg/Kg seems adequate for anaemia correction.
评估产品特性摘要中推荐的校正剂量是否足够,并在临床环境中确认从短效促红细胞生成素(ESA)转换为持续性促红细胞生成素受体激动剂(C.E.R.A)用于贫血慢性肾脏病(CKD)患者的推荐转换给药策略是否合适。
这是一项针对接受C.E.R.A(至少一剂)治疗的非透析和透析的贫血CKD患者进行的为期12个月的多中心、前瞻性观察性研究。
共纳入227例患者(非透析患者;n = 142;血液透析患者:n = 85)。本分析针对未使用过ESA的患者(非透析患者:n = 31)以及从其他ESA转换过来的患者(非透析患者:n = 63;血液透析患者:n = 57)进行。从其他ESA转换过来的透析和非透析患者接受的起始C.E.R.A剂量均低于推荐剂量,且在12个月期间保持稳定。既往ESA剂量越高,C.E.R.A剂量转换系数越有益。非透析CKD患者和透析患者中血红蛋白稳定在目标范围(11 - 13 g/dL)内的患者比例在12个月期间没有变化[基线时:42例(66.7%)和34例(59.6%);第6个月时:21例(55.3%)和26例(50.0%);第1个月时:20例(64.5%)和25例(69.4%)]。在未使用过ESA的患者中,研究期间平均体重调整后的C.E.R.A剂量(1.19 ± 0.49 µg/kg/月)与推荐剂量相似。C.E.R.A耐受性良好。
从短效ESA转换为低于推荐剂量的C.E.R.A,在非透析和血液透析CKD患者中均能有效维持目标血红蛋白水平,尤其是从较高ESA剂量转换时。每月1.2 µg/Kg的C.E.R.A剂量似乎足以纠正贫血。